Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Biomea Fusion, Inc. (BMEA) presented Phase I results of its BMF-650 drug, showing potential for separating gastrointestinal side effects from weight loss. The company's stock price reacted positively to the news.